Ranbaxy And Teva Expected To Team Up For At Risk Launch Of Generic Nexium - Analysts
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - India's top drug maker Ranbaxy Laboratories could be ready to team up with Israel's Teva Pharmaceuticals for an "at risk" launch of a generic version of AstraZeneca's heartburn blockbuster Nexium (esomeprazole), following tentative U.S. approval last month, Indian analysts say
You may also be interested in...
PharmAsia News India Pharma Roundup: Glenmark, FMRAI, Synchron/Parexel, Suven Life Sciences, Merck/Ranbaxy/Teva/Credit Suisse
NEW DELHI - Mumbai-based Glenmark Pharmaceuticals has split its corporate structure into speciality and generic units to better manage the "diverse businesses that had both attained a critical mass.